Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03580694 |
| Title | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Regeneron Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Regeneron Investigational Site | Chicago | Illinois | 60637 | United States | Details | |
| Regeneron Investigational Site | Grand Rapids | Michigan | 49546 | United States | Details | |
| Regeneron Investigational Site | Charlotte | North Carolina | 28204 | United States | Details | |
| Regeneron Investigational Site | Oklahoma City | Oklahoma | 73104 | United States | Details | |
| Regeneron Investigational Site | Nashville | Tennessee | 37203 | United States | Details | |
| Regeneron Investigational Site | San Antonio | Texas | 78229 | United States | Details |